Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations 24 November 2025
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results 06 November 2025
